Nice reminder of Afrezza uniqueness by another insulin developer:
"Not quite as fast as Afrezza®, but it lasts longer. "
This means the Dance product looks more like current mealtime insulins than super-fast acting Afrezza....

Dance BioPharm tried to IPO in 2014, filing a S1 for $75 M in April and withdrawing it in October.

I wish them good luck with the current design:
Did I put 2 drops of insulin or 3 ? Never mind mis-dosing....

Bank of America's deadline to cover its 9 M shorts at $5.55 is getting closer...

Agreed. For all the pseudo-negative we are hearing, price movement indicates someone is taking advantage of any relative lows...

Maybe tax-time after receiving many performance-based shares for successful approval, partnership, and launch of Afrezza...

Moreover this is less than 5% of his holding.

That one seems like a steal by the Chinese company, not any comparison to NioCorp...

GEM (TSX)/ GOLDF (OTC) has a market cap of around $9 M, and now 50.1% of its only project is to be owned by the Chinese partners.

Interesting choice of OTC ticker for a "REE" company.

yep, MOMO vs. LT investors

Impella 2.5 PMA for Elective and Urgent High Risk PCI Procedures

Right on time and on label, sweet !

Also no stigma for proud Afrezza users compared to injectable users who need to isolate themselves for their injection...

Also rapidity of action, quick peak, and optimal meal-length duration of action of Afrezza compared to injectables...

Buying today MNKD $10 expiring put close call...

Close at $5.26 + put at $4.65 - $10 = $0.09 gain/ share
x 2 M shares = $180,0000 less trading costs.

Imaging what would have happened without today's negativity on MNKD:

Close at $5.25... cost of trading as loss.
Close at $5.35... loss of $0.10/ share = $200,000 loss plus trading costs.

A day worth of work...

Doubling in open interest $10 put expiring today to 2.8 M...
1.5 M in new puts within hours of expiration... someone is making a big bet that the stock will go down....

Let's not forget the impact of the free samples on the current paying Rx...

I agree with you that more depth is needed in the Rx data before drawing conclusions.

First renewed Rx coming in...

$170 M cash Dec 31, including $50 M received since from Sanofi...

Very enlightening read, gives an nice historical perspective. Also a good reminder that Goldman is in this for its own interest...

I share that thinking with you: Rx picking up sweetly and the upcoming compulsory reduction in shorted shares will make the PPS go up and the shorties cry...

Only 6.5 months left for BoA to cover its 9 million short at $5.55

9 M BoA shares sold at $5.55 must be returned to Mannkind by Oct 01, 2015...

8K dated Aug 10, 2010

"Share Lending Agreement and Common Stock Offering
In connection with the offering of the Notes, on August 18, 2010, we entered into a share lending agreement (the “Share Lending Agreement”) with Bank of America, N.A. (the “Share Borrower”), an affiliate of Merrill Lynch, pursuant to which we lent 9,000,000 shares of our common stock (the “Borrowed Shares”) to the Share Borrower. The Share Borrower is obligated to return the borrowed shares (or identical shares or, in certain circumstances, the cash value thereof) to us on or about the 45th business day following the date as of which the entire principal amount of the Notes ceases to be outstanding, subject to extension or acceleration in certain circumstances or early termination at the Share Borrower’s option.
Also on August 18, 2010, we entered into an underwriting agreement (the “Underwriting Agreement”) with Merrill Lynch and the Share Borrower. Pursuant to the Underwriting Agreement, the Borrowed Shares were offered and sold to the public at a fixed price of $5.55 per share. We did not receive any proceeds from the sale of the Borrowed Shares to the public, but received a nominal lending fee of $90,000 pursuant to the Share Lending Agreement for the use by the Share Borrower of the Borrowed Shares. The Share Borrower or its affiliate received all of the net proceeds from the sale of Borrowed Shares to the public.

Timing of ESOP and RSU actions in change number of Shares outstanding, NOT because of bad events happening as implied elsewhere.

2014-10 K pp 90:
"The ESPP purchase for the period ending December 31, 2014 was initiated prior to year end but did not settle until January 5, 2015. As a result, the shares sold are reflected in the ESPP share reserves but is excluded from common stock outstanding as of December 31, 2014."

"Performance-based awards vest upon achieving pre-determined performance milestones, which are expected to occur over periods ranging from 11 months to 96 months from the date of grant. Only one milestone had not yet been achieved as of December 31, 2014, but is considered probable at such date. The 2013 Plan provides for full acceleration of vesting if an employee is terminated within three months of a change in control, as defined in the 2013 Plan. Subsequent to December 31, 2014, the company achieved the last performance-based milestone on February 3, 2015."

Let's not forget some Aug 2015 convertible debt could have been converted in February, before the bashing attack, as the stock was up to $7.90...

Hordes of lemmings running this way or that, like headless chickens.

Some shorting helping the move ?

Largo has been producing and shipping since last Sept.

Their problem is reimbursement of debt just about to start -unless reported again- and cash for CAPEX in 2015 and 2016.

Inflexion point before Oct 01 as BoA Merryl Lynch must return 9,000,000 shares to Mannkind by that date.

As these shares are used by shorts, that will have a big impact on them...

Timing effect of ESOP and RSU actions (10 K pp 90) in change number of Shares outstanding:

The ESPP purchase for the period ending December 31, 2014 was initiated prior to year end but did not settle until January 5, 2015. As a result, the shares sold are reflected in the ESPP share reserves but is excluded from common stock outstanding as of December 31, 2014.

Performance-based awards vest upon achieving pre-determined performance milestones, which are expected to occur over periods ranging from 11 months to 96 months from the date of grant. Only one milestone had not yet been achieved as of December 31, 2014, but is considered probable at such date. The 2013 Plan provides for full acceleration of vesting if an employee is terminated within three months of a change in control, as defined in the 2013 Plan. Subsequent to December 31, 2014, the company achieved the last performance-based milestone on February 3, 2015.

Possibly some Aug 2015 convertible debt has been converted in February, before the bashing attack, as the stock was up to $7.90...

with $0.02, you could have bought 1 Generex today, and be worse

Generex' buccal insulin has been going nowhere for a decade.

This is only a new formulation under development, still months away from human trials, even if they are reviving the old Ora-Lyn IND.

Recall Ora-Lyn (ultra-mini) Ph 3 US was initiated in 2008, completed in 2011, and submitted to the FDA in late 2011.
As of Jul 2014 10K: "We continue to have discussions with the FDA with respect to the pathway for regulatory approval, including any additional clinical or pharmacological studies that might be required to support regulatory approval or enhance marketing success."


Generex has $1.6 M cash as of Jan 31, 2015, an $1.6 M 6-month burn rate and 791,538,649 shares outstanding as of March 6, 2015...

Even at $0.02 PPS (+15% today thanks to the news, pump and dump ?), the market cap is only $15.8 M...

I never thought they would manage to muddle thru with nothing for so long...

Stock manipulators thrive on public data release delays.

Latest short interest as of Feb 27 released post Mar 10 close: +4.6 M shorts.
Big negative campaign Feb 24-Mar 10, stock goes down over $1.

Someone just has made a quick $4.6 M...

I seem to recall mention of taking a sulfonylurea (Amaryl ?) so the move to Afrezza would have been a long shot anyway.

Negative Posting Indicator never lies, one should always follow the reverse of its trend.

I can guess the next short interest number will be lower:
Obviously part of the recent bashing attack was to cover some of the increased Feb 27 shorts before they became public on Mar 10...

Time to buy now as NPI very high.

NPI: negative posting indicator

Quietly accumulating.

Shorty's goal is to make sure the convertible at $6.80 is not converted, hoping that would crush the stock to his benefit.

This is Navidea's share of LS sales, NOT the full LS sales.

LS sales greater than $3 M in q3 2014, at least the double.

$6.80 is a feared number for shorts:

Convertible debt maturing in Aug 2015, with a conversion price of $6.80 give them a stop-loss for 14.7 M CS.

BofA has 9 M shares to return to Mannkind within 45 days of the 2010 convertible debt ceasing to be outstanding.

Total at risk for shorts is 23.7 M shares, 28% of short interest.


The negative push since last week has been worth some $24 M to them...

This is that simple.

Invesco ETF rebalancing tonight, someone fronting them to make a quick buck ?

4 Biotechs Expected to See Huge Buying on PowerShares Rebalance
By Lee Jackson March 3, 2015 8:25 am EST

All the major money management firms that run exchange traded funds have to do regular quarterly rebalances to reset their portfolios to the proper allocation levels. When they do rebalance their holdings, it can introduce some big volatility to some of the stocks in the portfolio.

On the close Tuesday, Invesco will rebalance 15 of the firm’s PowerShares portfolios, which cover many of the major market sectors. A research note from the analysts at Cowen highlighted the top rebalance stocks by liquidity. We screened those stocks for the companies that would see the most amount of buying on a share basis, and four biotech companies stood out.

MannKind Corp. (NASDAQ: MNKD) is expected to see a massive buy of 2,230,300 shares of stock, which represents 40% of the 10-day average trading volume. The company has been an incredibly volatile stock over the past few years. MannKind finally launched its inhalable insulin product, which has been on the burner seemingly forever. The company’s marketing partner Sanofi has reported that demand has been higher than expected and that the sales force needs more samples for physicians.

The Thomson/First Call consensus price target for the stock is $8.66. Shares closed trading on Monday at $6.64.

Afrezza fast and discrete public use without stigma

FIst time Afrezza in public

So, your flat line from the last weekly Rx number projection gives $180,000 Afrezza revenue for q1 as of Feb 20.

No growth projected opens to very very very very good surprises

This seems sales to date rather than a Q1 model.

This number would assume all Rx are only for 1 month:
273 Rx x $220 = $60,000.

Using an usual 3 months supply:
273 x $220 x 3 = $180,000 to Feb 20.


I believe I saw some of you use $220 for 1 month supply recently.

Let's not forget these are for 4 days only, as Monday the 16th was Presidents' Day.
Proforma on 5 days, Afrezza is trending 141 paying, +32% w/w.

Further, recall samples are flying off the rep's hands for now...

Recall BofA has 9 M shares to return to Mannkind within 45 days of the 2010 convertible debt ceasing to be outstanding.

The convertible debt matures in Aug 2015, but with a conversion price of $6.80 this could happens faster...

9 M shares to cover explains public negative bias on the stock to keep the SP low while simultaneously buying on the market.

Not sure of possible correlations between the 2 launches:
- Afrezza, a new drug creating a new category of ultra-fast inhaled insulin in the spectrum of diabetes care, and
- Toujeo, a follow up formulation of Lantus, the current market leader in the basal insulin category, a well established multi-billion market.